Signal active
Organization
Contact Information
Overview
NeoChord is a medical device company that has developed a proprietary device that allows mitral valve repair to be performed on a beating heart through a 2 to 3-inch incision between the ribs in patients with severe, degenerative mitral valve regurgitation.
In contrast, most mitral valve repair procedures are performed through a 3 to 10-inch chest incision (sternotomy) which involves cutting through the sternum, opening the rib cage, stopping the heart and placing the patient on bypass.
Founded in 2007 and is based in St. Louis Park, MN.
About
Biotechnology, Health Care, Medical, Medical Device
2007
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
NeoChord headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Medical Device sector. The company focuses on Biotechnology and has secured $18.7B in funding across 208 round(s). With a team of 11-50 employees, NeoChord is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - NeoChord, raised $5.1M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
13
1
0
$89.9M
Details
6
NeoChord has raised a total of $89.9M in funding over 6 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2012 | Early Stage Venture | 850.0K | ||
2015 | Late Stage Venture | 20.0M | ||
2009 | Early Stage Venture | 3.4M | ||
2011 | Early Stage Venture | 5.1M |
Investors
NeoChord is funded by 12 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
NeoChord | - | FUNDING ROUND - NeoChord | 20.0M |
Deerfield | - | FUNDING ROUND - Deerfield | 20.0M |
NeoChord | - | FUNDING ROUND - NeoChord | 5.1M |
TGap Ventures | - | FUNDING ROUND - TGap Ventures | 5.1M |
Recent Activity
There is no recent news or activity for this profile.